tirzepatide glp1 gip GLP-1/GIP Rx GLP-1/GIP dual agonist tirzepatide normalizes

If your test results suggest higher individual sensitivity to GLP-1 effects, you can agree in advance on clearer pause-versus-continue criteria for future acute illness, reducing uncertainty and supporting faster, evidence-informed decisions when you're most vulnerable

Medicines in development: molecule & potential indication data as of April 28, 2022

Regular check-ins with your healthcare provider are crucial for long-term success

Concomitant use with other GLP-1 receptor agonists is not recommended

Tirzepatide carries several absolute and relative contraindications that clinicians must carefully evaluate before prescribing